AERA: Efficacy of Rotations Between Abiraterone Acetate and Apalutamide in mCRPC Patients

Sponsor
University of Athens (Other)
Overall Status
Withdrawn
CT.gov ID
NCT03173859
Collaborator
(none)
0
2
36

Study Details

Study Description

Brief Summary

A randomized phase II study comparing the sequential use of abiraterone followed after progression by apalutamide with alternating cycles of abiraterone and apalutamide

Condition or Disease Intervention/Treatment Phase
Phase 2

Detailed Description

This is an open-label, randomized phase II study to investigate the feasibility of alternating cycles of treatment with abiraterone plus prednisone and apalutamide compared to sequential treatment of abiratereone plus prednisone followed by apalutamide. 7 centers in Greece will participate in the study.

The study population consists of adult patients (over 18 years old) with histologically confirmed metastatic prostate adenocarcinoma who have disease progression - as defined by PCWG2 criteria - despite androgen deprivation therapy and who have not received prior therapy for their castration resistant disease.

The purpose of the study is to determine the progression free survival, feasibility and safety profile of the experimental arm compared to standard of care.

In the experimental arm alternating treatment will consist of repeating cycles of 24 weeks of treatment consisting of 12 weeks of abiraterone acetate 1000mg orally qd and prednisone 5mg orally bid, followed by 12 weeks of apalutamide 240 mg per day. There will be no wash out period between cycles.

The comparative arm will be the standard regimen of abiraterone 1000mg orally qd plus prednisone 5mg orally bid until progression, followed thereafter by apalutamide 240mg orally qd until progression.

Study Design

Study Type:
Interventional
Actual Enrollment :
0 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
None (Open Label)
Primary Purpose:
Treatment
Official Title:
A Randomized Phase II Study to Investigate the Efficacy of Rotations Between Abiraterone Acetate and Apalutamide Versus Sequential Administration in Chemo-naïve Metastatic Castration Resistant Prostate Cancer Patients
Anticipated Study Start Date :
Jan 1, 2018
Anticipated Primary Completion Date :
Dec 31, 2020
Anticipated Study Completion Date :
Dec 31, 2020

Arms and Interventions

Arm Intervention/Treatment
Experimental: Rotational

Abiraterone acetate 1000mg qD and prednisone 5mg bid administered orally starting on Day 1 of Cycle 1 for 3 cycles, followed by apalutamide 240mg qD orally for 3 cycles. The duration of each cycle is 28 days

Drug: Abiraterone
Abiraterone acetate 1000mg qD and prednisone 5mg bid administered orally
Other Names:
  • Zytiga
  • Drug: Apalutamide
    apalutamide 240mg qD orally

    Active Comparator: Sequential

    Abiraterone acetate 1000mg qD and prednisone 5mg bid administered orally starting on Day 1 of Cycle 1 until disease progression, followed by apalutamide 240mg qD orally until second disease progression.

    Drug: Abiraterone
    Abiraterone acetate 1000mg qD and prednisone 5mg bid administered orally
    Other Names:
  • Zytiga
  • Drug: Apalutamide
    apalutamide 240mg qD orally

    Outcome Measures

    Primary Outcome Measures

    1. Radiographic progression-free survival [Estimated up to 24 months]

      time until radiographic progression as assessed by PCWG2 criteria

    Secondary Outcome Measures

    1. Overall survival [estimated up to 36 months]

      time until death or lost to follow up

    2. Time to cytotoxic therapy initiation [Estimated up to 24 months]

      time until the beginning of chemotherapy

    3. Time until PSA progression [Estimated up to 24 months]

      time until PSA progression as defined by PCWG2 criteria

    4. Incidence, nature and severity of AEs [Estimated up to 24 months]

      recording of all AE/SAEs

    Other Outcome Measures

    1. Patient reported outcomes assessed using the FACT-P and EQ-5D-5L questionnaires [Estimated up to 24 months]

      Differences in FACT-P questionnaires between treatment groups

    2. Number of Circulating Tumor Cells (CTCs) and ARv7 analysis in CTCs from peripheral blood at baseline evaluation, first and second disease progression in Arm 2 and disease progression in Arm 1 (PD1). [Estimated up to 24 months]

      Correlation of CTCs number and ARv7 expression with rPFS and OS in these patients

    3. Patient reported outcomes assessed using the EQ-5D-5L questionnaires [Estimated up to 24 months]

      Differences in EQ-5D-5L questionnaires between treatment groups

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    18 Years and Older
    Sexes Eligible for Study:
    Male
    Accepts Healthy Volunteers:
    No
    Inclusion Criteria:
    • Signed Informed Consent Age >18 years Histologically confirmed metastatic or advanced prostate cancer adenocarcinoma that has received no treatment for the castration resistant disease and has progressed during treatment with complete androgen blockade (luteinizing hormone releasing hormone agonist or antagonist and an antiandrogen eg. Bicalutamide).

    Availability of a representative formalin-fixed, paraffin-embedded tumor specimen (FFPE) that enabled definitive diagnosis of prostate cancer.

    Two rising PSA levels >2ng/ml measured 1 week apart during or following the most recent prior therapy for prostate cancer (PCWG2 criteria) or radiographic evidence of disease progression in bone with or without biochemical disease progression on the basis of the PSA value.

    Ongoing androgen deprivation, with serum testosterone <50ng/dl ECOG performance status 0-1 at screening Adequate hematologic and organ function within 14 days before the first study treatment (hematologic parameters must be assessed >14 days after a prior transfusion, if any) as defined by

    • Hemoglobin >9g/dl

    • Neutrophils >1500/μL

    • Platelet count >100000/μL

    • Total bilirubin <1,5xULN with the following exception:

    o Patients with known Gilbert syndrome who have serum bilirubin<3xULN

    • AST and ALT<2,5xULN with the following exception

    o Patients with bone-only metastasis may have AST<5xULN, provided that ALT <2,5xULN and total bilirubin <1,5xULN

    • Serum albumin >3g/dl

    • Serum potassium ≥3.5mmol/L

    • Serum creatinine <1,5xULN or creatinine clearance of >50ml/min based on Cockcroft-Gault equation

    • Agreement by patient and/or partner to use an effective form of contraception including surgical sterilization, reliable barrier method, birth control pills, contraceptive hormone implants or true abstinence and to continue its use for the duration of the study and for 6 months after the last dose of study treatment.

    Exclusion Criteria:
    • Small cell or neuroendocrine prostate carcinoma Inability or unwillingness to swallow pills Malabsorption syndrome or other condition that would interfere with enteral absorption Congenital long QT syndrome or QTc>480msec NYHA Class II to IV heart failure or LVEF <50% or ventricular arrhythmia requiring medication Previous therapy for prostate cancer with CYP17 inhibitors including ketoconazole or investigational agents (VMT-VT-464, Orteronel etc) or novel antiandrogens (enzalutamide of OMD-208) for more than 7 days Presence of visceral metastasis History of another invasive cancer within 3 years from screening, with the exception of fully treated cancers with a remote probability of recurrence Duration of previous Androgen Deprivation Therapy <12months Active infection requiring IV antibiotics
    Clinically significant cardiovascular disease including the following:
    • unstable angina,

    • myocardial infarction within 6 months from screening, or

    • cerebrovascular accident within 6 months from screening Major surgical procedure within 4 weeks prior to initiation of study treatment Treatment with an investigational agent within 4 weeks prior to initiation of study treatment Unresolved, clinical significant toxicity from prior treatment Hypersensitivity reaction to the active pharmaceutical ingredient or any of the tablet components Any medical condition that restrain the patient to comply with study and follow-up procedures Inability to comply with study and follow up procedures

    Contacts and Locations

    Locations

    No locations specified.

    Sponsors and Collaborators

    • University of Athens

    Investigators

    None specified.

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    Aristotelis Bamias, Professor, University of Athens
    ClinicalTrials.gov Identifier:
    NCT03173859
    Other Study ID Numbers:
    • 70/3/14073
    • 2017-000443-41
    First Posted:
    Jun 2, 2017
    Last Update Posted:
    Nov 18, 2020
    Last Verified:
    Nov 1, 2020
    Individual Participant Data (IPD) Sharing Statement:
    No
    Plan to Share IPD:
    No
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    No
    Product Manufactured in and Exported from the U.S.:
    No
    Keywords provided by Aristotelis Bamias, Professor, University of Athens
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of Nov 18, 2020